Cargando…

Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model

INTRODUCTION: Insulin-like peptide 5 (INSL5) is a peptide hormone with proposed actions in glucose homeostasis and appetite regulation via its cognate receptor, relaxin family peptide receptor 4 (RXFP4). Here, we look for evidence for their involvement in the immune system using a mouse model. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Vahkal, Brett, Yegorov, Sergey, Onyilagha, Chukwunonso, Donner, Jacqueline, Reddick, Dean, Shrivastav, Anuraag, Uzonna, Jude, Good, Sara V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841425/
https://www.ncbi.nlm.nih.gov/pubmed/33519716
http://dx.doi.org/10.3389/fendo.2020.610672
_version_ 1783643804132179968
author Vahkal, Brett
Yegorov, Sergey
Onyilagha, Chukwunonso
Donner, Jacqueline
Reddick, Dean
Shrivastav, Anuraag
Uzonna, Jude
Good, Sara V.
author_facet Vahkal, Brett
Yegorov, Sergey
Onyilagha, Chukwunonso
Donner, Jacqueline
Reddick, Dean
Shrivastav, Anuraag
Uzonna, Jude
Good, Sara V.
author_sort Vahkal, Brett
collection PubMed
description INTRODUCTION: Insulin-like peptide 5 (INSL5) is a peptide hormone with proposed actions in glucose homeostasis and appetite regulation via its cognate receptor, relaxin family peptide receptor 4 (RXFP4). Here, we look for evidence for their involvement in the immune system using a mouse model. METHODS: In silico analyses: we queried public databases for evidence of expression of INSL5-RXFP4 in immune system tissues/cells (NCBI’s SRA and GeoProfiles) and disorders (EMBO-EBI) and performed phylogenetic footprinting to look for evidence that they are regulated by immune-associated transcription factors (TFs). Experimental analyses: We characterized the expression and correlation of INSL5/RXFP4 and other immune system markers in central and peripheral immune organs from C57/bl6 mice in seven cohorts. We tested whether fluctuations in circulating INSL5 induce an immune response, by injecting mice with 30 μg/kg of INSL5 peptide in the peritoneum, and examining levels of immune markers and metabolic peptides in plasma. Lastly, we quantified the expression of Rxfp4 in T-cells, dendritic cells and cell lines derived from human and mouse and tested the hypothesis that co-incubation of ANA-1 cells in INSL5 and LPS alters cytokine expression. RESULTS: We find Insl5 expression only in thymus (in addition to colon) where its expression was highly correlated with Il-7, a marker of thymocyte development. This result is consistent with our in silico findings that Insl5 is highly expressed in thymic DP, DN thymocytes and cortical TEC’s, and with evidence that it is regulated by thymocyte-associated TF’s. We find Rxfp4 expression in all immune organs, and moderately high levels in DCs, particularly splenic DCs, and evidence that it is regulated by immune-associated TF’s, such as STAT’s and GATA. Systemic effects: We observed significantly elevated concentrations of blood GLP-1, GIP, GCG and PYY following intraperitoneal injection of INSL5, and significantly altered expression of cytokines IL-5, IL-7, M-CSF, IL-15, IL-27 and MIP-2. Immune cell effects: Incubation of ANA-1 cells with INSL5 impeded cell growth and led to a transient elevation of IL-15 and sustained reduction in IL-1β, IL-6 and TNFα. CONCLUSION: We propose that INSL5-RXFP4 play a novel role in both central and peripheral immune cell signaling.
format Online
Article
Text
id pubmed-7841425
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78414252021-01-29 Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model Vahkal, Brett Yegorov, Sergey Onyilagha, Chukwunonso Donner, Jacqueline Reddick, Dean Shrivastav, Anuraag Uzonna, Jude Good, Sara V. Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Insulin-like peptide 5 (INSL5) is a peptide hormone with proposed actions in glucose homeostasis and appetite regulation via its cognate receptor, relaxin family peptide receptor 4 (RXFP4). Here, we look for evidence for their involvement in the immune system using a mouse model. METHODS: In silico analyses: we queried public databases for evidence of expression of INSL5-RXFP4 in immune system tissues/cells (NCBI’s SRA and GeoProfiles) and disorders (EMBO-EBI) and performed phylogenetic footprinting to look for evidence that they are regulated by immune-associated transcription factors (TFs). Experimental analyses: We characterized the expression and correlation of INSL5/RXFP4 and other immune system markers in central and peripheral immune organs from C57/bl6 mice in seven cohorts. We tested whether fluctuations in circulating INSL5 induce an immune response, by injecting mice with 30 μg/kg of INSL5 peptide in the peritoneum, and examining levels of immune markers and metabolic peptides in plasma. Lastly, we quantified the expression of Rxfp4 in T-cells, dendritic cells and cell lines derived from human and mouse and tested the hypothesis that co-incubation of ANA-1 cells in INSL5 and LPS alters cytokine expression. RESULTS: We find Insl5 expression only in thymus (in addition to colon) where its expression was highly correlated with Il-7, a marker of thymocyte development. This result is consistent with our in silico findings that Insl5 is highly expressed in thymic DP, DN thymocytes and cortical TEC’s, and with evidence that it is regulated by thymocyte-associated TF’s. We find Rxfp4 expression in all immune organs, and moderately high levels in DCs, particularly splenic DCs, and evidence that it is regulated by immune-associated TF’s, such as STAT’s and GATA. Systemic effects: We observed significantly elevated concentrations of blood GLP-1, GIP, GCG and PYY following intraperitoneal injection of INSL5, and significantly altered expression of cytokines IL-5, IL-7, M-CSF, IL-15, IL-27 and MIP-2. Immune cell effects: Incubation of ANA-1 cells with INSL5 impeded cell growth and led to a transient elevation of IL-15 and sustained reduction in IL-1β, IL-6 and TNFα. CONCLUSION: We propose that INSL5-RXFP4 play a novel role in both central and peripheral immune cell signaling. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7841425/ /pubmed/33519716 http://dx.doi.org/10.3389/fendo.2020.610672 Text en Copyright © 2021 Vahkal, Yegorov, Onyilagha, Donner, Reddick, Shrivastav, Uzonna and Good http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Vahkal, Brett
Yegorov, Sergey
Onyilagha, Chukwunonso
Donner, Jacqueline
Reddick, Dean
Shrivastav, Anuraag
Uzonna, Jude
Good, Sara V.
Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
title Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
title_full Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
title_fullStr Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
title_full_unstemmed Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
title_short Immune System Effects of Insulin-Like Peptide 5 in a Mouse Model
title_sort immune system effects of insulin-like peptide 5 in a mouse model
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841425/
https://www.ncbi.nlm.nih.gov/pubmed/33519716
http://dx.doi.org/10.3389/fendo.2020.610672
work_keys_str_mv AT vahkalbrett immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT yegorovsergey immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT onyilaghachukwunonso immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT donnerjacqueline immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT reddickdean immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT shrivastavanuraag immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT uzonnajude immunesystemeffectsofinsulinlikepeptide5inamousemodel
AT goodsarav immunesystemeffectsofinsulinlikepeptide5inamousemodel